USClinicalTrials.govClinical trialPhase 3Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Official record
- Identifier
NCT06646276- Recruiting locations
countries
United StatesArgentinaAustraliaAustriaBelgiumBrazilCanadaChileChinaCzechiaFranceGermanyGreeceIndiaItalyJapanMalaysiaMexicoNetherlandsPolandRomaniaSouth KoreaSpainSwitzerlandTurkey (Türkiye)United Kingdom- Interventions studied
- BMS-986489 (Atigotatug+Nivolumab)AtezolizumabCarboplatinEtoposide
- Lead sponsor
- Bristol-Myers Squibb
- Target enrolment
- 530 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Status
- Recruiting
- First posted
- Oct 17, 2024
- Last updated on the registry
- Sep 11, 2026
- Age
- 18 Years
- Sex
- ALL
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system Exclusion Criteria * Participants have already received certain types of treatment for extensive stage small cell lung cancer * Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy * Other protocol-defined Inclusion/Exclusion criteria apply.
- Indexed under
- Lung Cancer